BUSINESS-WIRE
2.4.2018 15:02:08 CEST | Business Wire | Press release
Business Wire and TrendKite have entered into a reciprocal sales arrangement, enabling clients to leverage the industry’s most comprehensive news distribution platform and then gauge the effectiveness of their campaign using the advanced analytics of TrendKite’s Intelligent Communications Platform .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005104/en/
The agreement brings together two influential service providers serving the public relations industry: Business Wire, the global leader in press release distribution, and TrendKite, a startup that has upended the legacy monitoring industry with its technological innovation and data-driven approach to quantifying media outreach results.
Business Wire and TrendKite will offer select service offerings under the terms of the agreement.
TrendKite clients will have the opportunity to reach audiences worldwide via Business Wire, which provides access to dozens of international and national news agencies, as well as leading financial information platforms, news syndicators, content aggregation services and databases.
Business Wire clients will be able to take advantage of the TrendKite Intelligent Communications Platform to measure the effectiveness of their press releases and public relations campaigns and identify and target key journalists and influencers to pitch. TrendKite helps organizations make better data-informed decisions about their communications programs and measure the business impact and bottom line results of their earned media. TrendKite’s innovative services transform 4.7 million global sources into actionable intelligence with customized dashboards, interactive reports, social amplification, Google and Adobe Analytics integrations and PR Attribution , which assesses the true impact of a media mention by measuring site traffic influenced by earned media. Going a step further, TrendKite has created Pinpoint Contacts, an artificial intelligence-powered influencer and journalist database, to assist communicators in identifying relevant contacts.
“TrendKite is a forward-thinking company that is aligned with Business Wire’s perspective on the future of content delivery and monitoring solutions,” said Geff Scott , Business Wire’s chief executive officer. “Our relationship with TrendKite promises to bring value to clients of both companies, providing best-of-breed solutions that will create new industry standards.”
“Our customers rely on news distribution as part of their plan to take a story to market, but have trouble knowing if their press releases are gaining earned coverage that drives business results,” said Erik Huddleston, TrendKite’s chief executive officer. “Business Wire’s status as the industry leader, combined with their measurably superior results and their understanding of the earned media landscape, make them a natural partner for TrendKite and a high value for our customers.”
About Business Wire:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure . Investor relations, public relations, public policy and marketing professionals rely on Business Wire to accurately distribute market-moving news and multimedia, host online newsrooms and IR websites , build content marketing platforms , generate social engagements and provide audience analysis that improves interaction with specified target markets. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 29 offices worldwide to securely meet the varying needs of communications professionals and news consumers.
Learn more at services.BusinessWire.com and Tempo , the Business Wire resource for industry trends; follow updates on Twitter: @businesswire or on Facebook .
About TrendKite
Founded in 2012 in Austin, Texas, TrendKite is the Intelligent Communications Platform that puts earned media at the heart of the marketing mix. By harnessing artificial intelligence and big data analytics to optimize the impact public relations has on a brand’s reputation, website traffic and business goals, TrendKite is transforming the way the world views earned media.
As a venture backed, high traction startup, TrendKite is disrupting a huge existing market while helping companies like Nike, Google, Delta, SXSW and thousands more turn PR coverage into real business impact.
Click here to subscribe to Mobile Alerts for Business Wire .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005104/en/
Contact:
TrendKite
Lacey Miller
lacey@trendkite.com
or
Business
Wire
Neil Hershberg, +1 212-752-9600, Ext. 1434
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom